Recombinant activated factor VII use in critically ill patients: Clinical outcomes and thromboembolic events;Uso de factor VII recombinante activado en pacientes críticos: Resultados clínicos y eventos tromboembólicos

Annals of Pharmacotherapy

Volumn 47, Issue 4, 2013, Pages 447-454

  Brophy, Gretchen M ^a   Candeloro, Christina L ^b   Robles, Jaime R ^a   Brophy, Donald F ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 7A;

ACUTE HEART INFARCTION; ACUTE KIDNEY FAILURE; ADULT; ARTICLE; ARTIFICIAL VENTILATION; BLEEDING; BLOOD CLOTTING DISORDER; BLOOD TRANSFUSION; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; COMORBIDITY; CONTROLLED STUDY; CRITICALLY ILL PATIENT; DATA BASE; DEMOGRAPHY; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEART INFARCTION; HEMODIALYSIS; HOSPITAL; HUMAN; INTENSIVE CARE UNIT; LENGTH OF STAY; LIVER CIRRHOSIS; LUNG EMBOLISM; LUNG INFARCTION; MAJOR CLINICAL STUDY; MALE; NURSE; PHLEBITIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK; SEPSIS; SIDE EFFECT; THROMBOPHLEBITIS; TRAUMATIC BRAIN INJURY; TREATMENT OUTCOME; VEIN EMBOLISM; VEIN THROMBOSIS;

EID: 84876207995     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1R729     Document Type: Article

References (45)

1. Levi M, Opal SM. Coagulation abnormalities in critically ill patients. Crit Care 2006;10:222. doi: 10.1186/cc4975
2. Product information. NovoSeven (coagulant factor VIIa, recombinant). Princeton, NJ: Novo Nordisk A/S, September 1999.
3. Logan AC, Yank V, Stafford RS. Off-label use of recombinant factor VIIa in U.S. hospitals: analysis of hospital records. Ann Intern Med 2011;154:516-22.
4. Mohr AM, Holcomb JB, Dutton RP, Duranteau J. Recombinant activated factor VIIa and hemostasis in critical care: a focus on trauma. Crit Care 2006;9:S37-42. doi: 10.1186/cc3784
5. Brown CV, Sowery L, Curry E, et al. Recombinant factor VIIa to correct coagulopathy in patients with traumatic brain injury presenting to outlying facilities before transfer to the regional trauma center. Am Surg 2012;78:57-60.
6. Stein DM, Dutton RP, Kramer ME, Scalea TM. Reversal of coagulopathy in critically ill patients with traumatic brain injury: recombinant factor VIIa is more cost-effective than plasma. J Trauma 2009;66:63-72. doi: 10.1097/TA.0b013e318191bc8a
7. Stein DM, Dutton RP, Hess JR, Scalea TM. Low-dose recombinant factor VIIa for trauma patients with coagulopathy. Injury 2008;39:1054-61. doi: 10.1016/j.injury.2008.03.032
8. Boffard KD, Riou B, Warren B, et al. Recombinant factor VIIa as adjunctive therapy for bleeding control in severely injured trauma patients: two parallel randomized, placebo-controlled, double-blind clinical trials. J Trauma 2005;59:8-15.
9. Dutton RP, McCunn M, Hyder M, et al. Factor VIIa for correction of traumatic coagulopathy. J Trauma 2004;57:709-18.
10. Harrison TD, Laskosky J, Jazaeri O, Pasquale MD, Cipolle M. 'Low dose' recombinant activated factor VII results in less blood and blood product use in traumatic hemorrhage. J Trauma 2005;59:150-4.
11. Gunst M, Pickard B, White C. Recombinant activated factor VII: an adjunct to damage control in the coagulopathic trauma patient (abstract). J Trauma 2004;58:217.
12. Narayan RK, Maas AI, Marshall LF, et al. Recombinant factor VIIA in traumatic intracerebral hemorrhage: results of a dose escalation clinical trial. Neurosurgery 2008;62:776-86. doi: 10.1227/01.neu.0000316898.78371.74
13. Gill R, Herbertson M, Vuylsteke A, et al. Safety and efficacy of recombinant activated factor VII: a randomized placebo-controlled trial in the setting of bleeding after cardiac surgery. Circulation 2009;120:21-7. doi: 10.1161/CIRCULATIONAHA.108.834275
14. Bosch J, Thabut D, Bendtsen F, et al. Recombinant factor VIIa for upper gastrointestinal bleeding in patients with cirrhosis: a randomized, doubleblind trial. Gastroenterology 2004;127:1123-30. doi: 10.1053/j.gastro.2004.07.015
15. Bosch J, Thabut D, Albillos A, et al. Recombinant factor VIIa for variceal bleeding in patients with advanced cirrhosis: a randomized, controlled trial. Hepatology 2008;47:1604-14. doi: 10.1002/hep.22216
16. Lodge JP, Jonas S, Jones RM, et al. Efficacy and safety of repeated perioperative doses of recombinant factor VIIa in liver transplantation. Liver Transpl 2005;11:973-9. doi: 10.1002/lt.20470
17. Lodge JP, Jonas S, Oussoultzoglou E, et al. Recombinant coagulation factor VIIa in major liver resection: a randomized, placebo-controlled, double-blind clinical trial. Anesthesiology 2005;102:269-75.
18. Planinsic RM, van der Meer J, Testa G, et al. Safety and efficacy of a single bolus administration of recombinant factor VIIa in liver transplantation due to chronic liver disease. Liver Transpl 2005;11:895-900. doi: 10.1002/lt.20458
19. Shao YF, Yang JM, Chau GY, et al. Safety and hemostatic effect of recombinant activated factor VII in cirrhotic patients undergoing partial hepatectomy: a multicenter, randomized, double-blind, placebo-controlled trial. Am J Surg 2006;191:245-9. doi: 10.1016/j.amjsurg.2005.10.019
20. Mayer SA, Brun NC, Begtrup K, et al. Recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med 2005;352:777-85. doi: 10.1056/NEJMoa042991
21. Mayer SA, Brun NC, Broderick J, et al. Safety and feasibility of recombinant factor VIIa for acute intracerebral hemorrhage. Stroke 2005;36: 74-9. doi: 10.1161/01.STR.0000149628.80251.b8
22. Mayer SA, Brun NC, Broderick J, et al. Recombinant activated factor VII for acute intracerebral hemorrhage: US phase IIA trial. Neurocrit Care 2006;4:206-14. doi: 10.1385/NCC:4:3:206
23. Mayer SA, Brun NC, Begtrup K, et al. Efficacy and safety of recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med 2008;358:2127-37. doi: 10.1056/NEJMoa0707534
24. Pickard JD, Kirkpatrick PJ, Melsen T, et al. Potential role of Novo Seven in the prevention of rebleeding following aneurysmal subarachnoid haemorrhage. Blood Coag Fibrinolysis 2000;11(suppl 1):S117-20.
25. Dager WE, King JH, Regalia RC, et al. Reversal of elevated international normalized ratios and bleeding with low-dose recombinant activated factor VII in patients receiving warfarin. Pharmacotherapy 2006;26:1091-8. doi: 10.1592/phco.26.8.1091
26. Ilyas C, Beyer GM, Dutton RP, Scalea TM, Hess JR. Recombinant factor VIIa for warfarin-associated intracranial bleeding. J Clin Anesth 2008; 20:276-9. doi: 10.1016/j.jclinane.2007.12.012
27. Brody DL, Aiyagari V, Shackleford AM, Diringer MN. Use of recombinant factor VIIa in patients with warfarin-associated intracranial hemorrhage. Neurocrit Care 2005;2:263-7. doi: 10.1385/NCC:2:3:263
28. Nishijima DK, Dager WE, Schrot RJ, Holmes JF. The efficacy of factor VIIa in emergency department patients with warfarin use and traumatic intracranial hemorrhage. Acad Emerg Med 2010;17:244-51. doi: 10.1111/j.1553-2712.2010.00666.x
29. Robinson MT, Rabinstein AA, Meschia JF, Freeman WD. Safety of recombinant activated factor VII in patients with warfarin-associated hemorrhages of the central nervous system. Stroke 2010;41:1459-63. doi: 10.1161/STROKEAHA.110.581538
30. Da'as N, Misgav M, Kalish Y, Varon D. Recombinant factor VIIa for rapid reversal of anticoagulant effect in patients with intracranial hemorrhage: the Israeli experience and review of the literature. Isr Med Assoc J 2006;8:807-11.
31. Ingerslev J, Vanek T, Culic S. Use of recombinant factor VIIa for emergency reversal of anticoagulation. J Postgrad Med 2007;53:17-22. doi: 10.4103/0022-3859.30322
32. Yank V, Tuohy CV, Logan AC, et al. Systematic review: benefits and harms of in-hospital use of recombinant factor VIIa for off-label indications. Ann Intern Med 2011;154:529-40.
33. Ferrari L, Podda GM. Off-label use of recombinant activated coagulation factor VII for bleeding may raise the risk of arterial thrombosis. Intern Emerg Med 2011;6:261-2. doi: 10.1007/s11739-011-0593-8
34. Johansson PI. Off-label use of recombinant factor VIIa for treatment of haemorrhage: results from randomized clinical trials. Vox Sang 2008;95: 1-7. doi: 10.1111/j.1423-0410.2008.01063.x
35. Lin Y, Stanworth S, Birchall J, et al. Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia. Cochrane Database Syst Rev 2011(2):CD005011. doi: 10.1002/14651858.CD005011.pub3
36. Logan AC, Goodnough LT. Recombinant factor VIIa: an assessment of evidence regarding its efficacy and safety in the off-label setting. Hematol Am Soc Hematol Educ Program 2010;2010:153-9. doi: 10.1182/asheducation-2010.1.153
37. Grounds RM, Bolan C. Clinical experiences and current evidence for therapeutic recombinant factor VIIa treatment in nontrauma settings. Crit Care 2005;9:S29-36. doi: 10.1186/cc3783
38. Levi M, Levy JH, Andersen HF, Truloff D. Safety of recombinant activated factor VII in randomized clinical trials. N Engl J Med 2010;363: 1791-800. doi: 10.1056/NEJMoa1006221
39. Willis CD, Cameron PA, Phillips LE. Clinical guidelines and off-license recombinant activated factor VII: content, use, and association with patient outcomes. J Thromb Haemost 2009;7:2016-22. doi: 10.1111/j.1538-7836.2009.03632.x
40. 3M Health Information Systems. All patient refined diagnosis related groups (APR-DRG), version 24.0, methodology overview. Wallingford, CT: 3M Health Information Systems, 2006.
41. Brophy DF, Harpe SE, Carl DE, Brophy GM. An epidemiological study of anemia and renal dysfunction in patients admitted to ICUs across the United States. Anemia 2012;2012:938140. doi: 1155/2012/938140.
42. Rubin DB. Matching to remove bias in observational studies. Biometrics 1973;29:159-84.
43. Stuart EA. Matching methods for causal inference: a review and a look forward. Stat Sci 2010;25:1-21. doi: 10.1214/09-STS313
44. Agresti A. Categorical data analysis. 2nd ed. New York, NY: Wiley Interscience, 2002.
45. Martinussen T, Scheike TH. Dynamic regression models for survival data. New York, NY: Springer, 2006.